克睿基因 Cure Genetics is a clinical-stage biotech founded in Suzhou in 2016 that develops cell and gene therapies for solid tumors and genetic diseases. It runs two proprietary platforms: AIMS, an allogeneic CAR-NKT cell therapy approach aimed at hard-to-treat solid tumors, and VELP, a directed-evolution AAV vector platform that builds high-quality viral libraries for tissue-targeted gene delivery to the nervous system, heart, and kidney. Its lead programs include CGC729 (anti-CD70 CAR-NKT for renal cell carcinoma) and CGC-602 (a PD-1-IL-2v bispecific antibody).
Keythera (Suzhou) Biopharmaceuticals is a clinical-stage biotech building first-in-class small molecule drugs for cancer and autoimmune disease. Its core edge is ADMS - Affinity Detection by Mass Spectroscopy - an affinity-based high-throughput screening platform that can screen up to 250,000 compounds per day per workstation and fuses bioinformatics, structural chemistry, computer-aided drug design and AI to find and optimize drug candidates faster and at lower risk. Founded in 2020 by industry veteran Dr. Yongqi Deng, the company has built six pipelines, advanced its lead EP4 antagonist KF-0210 into the clinic, and raised roughly RMB 100M in Series A funding.